List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 309 studies with search of: "Trastuzumab"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Breast
Interventions: Drug: 0.04 mg/kg CpG 7909;   Drug: Herceptin®;   Drug: 0.08 mg/kg CpG 7909;   Drug: Herceptin®;   Drug: 0.12 mg/kg CpG 7909;   Drug: Herceptin®;   Drug: 0.16 mg/kg CpG 7909;   Drug: Herceptin®
2 Terminated Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Condition: Carcinoma, Metastatic Breast
Interventions: Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®;   Drug: CPG 7909;   Drug: Herceptin®
3 Recruiting Six vs 12 Months of Transtuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil;   Drug: Granulocyte-colony stimulating growth factor;   Drug: Trastuzumab
4 Active, not recruiting A Dose Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and HER2 Positive Female Patients
Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin];   Drug: trastuzumab [Herceptin]
5 Recruiting The Synergism Or Long Duration (SOLD) Study
Condition: Breast Neoplasms
Interventions: Drug: trastuzumab (9 weeks) + docetaxel;   Drug: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
6 Recruiting A Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease
Condition: Metastatic Breast Cancer
Interventions: Drug: docetaxel;   Drug: trastuzumab;   Drug: trastuzumab-MCC-DM1
7 Recruiting A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone & Trastuzumab;   Drug: Docetaxel & Trastuzumab
8 Recruiting BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Condition: Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
9 Recruiting Trastuzumab Optimization Trial in Breast Cancer
Condition: Metastatic or Locally Advanced Breast Cancer
Intervention: Drug: trastuzumab
10 Recruiting Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: nab-paclitaxel;   Drug: trastuzumab
11 Active, not recruiting Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Condition: Ductal Carcinoma In Situ
Intervention: Drug: Herceptin (Trastuzumab)
12 Recruiting Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-Positive Breast Cancer (Study P05048AM2)
Condition: Breast Neoplasm
Interventions: Drug: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab;   Drug: PLD, cyclophosphamide, trastuzumab, paclitaxel
13 Recruiting Efficacy and Safety Study Evaluating IPI-504 With Trastuzumab in Patients With Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Cancer of the Breast
Intervention: Drug: IPI-504 and Trastuzumab
14 Completed Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Gemcitabine;   Drug: Trastuzumab;   Drug: Cisplatin
15 Active, not recruiting Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: doxorubicine, cyclophosphamide, docetaxel;   Drug: doxorubicine, cyclophosphamide, trastuzumab, docetaxel;   Drug: trastuzumab, docetaxel, carboplatin
16 Completed Randomized Trial With Trastuzumab Versus Observation in Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Trastuzumab
17 Recruiting Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Ixabepilone;   Drug: Trastuzumab;   Drug: Carboplatin
18 Recruiting Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles;   Drug: Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles
19 Recruiting Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Trastuzumab (Herceptin)
20 Recruiting Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Drug: Trastuzumab;   Drug: RAD001

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services